文献速递造血干细胞移植与细胞治疗淋巴瘤

第三方2型固有淋巴细胞预防和治疗胃肠道GVHD

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD.
PubMed 文献 · Blood Adv · 2021-01-01

急性移植物抗宿主病(aGVHD)是异基因造血干细胞移植(allo-HSCT)的重要并发症,胃肠道常受累,类固醇难治性aGVHD患者预后极差。本研究显示第三方2型固有淋巴细胞(ILC2)可提高allo-HSCT受者生存率,需至少4次每周输注,其功能依赖IL-13和双调蛋白表达。

要点

  • 第三方ILC2细胞可预防和治疗胃肠道aGVHD,无需供者来源。
  • 至少需4次每周输注ILC2细胞才能延长生存。
  • ILC2功能完全依赖IL-13和双调蛋白同时表达。

核心结论

  • 第三方ILC2细胞可提高allo-HSCT受者生存率,为aGVHD预防提供新途径。

研究设计与样本

  • 基于前期供者ILC2研究的临床前实验,探索第三方ILC2细胞对allo-HSCT受者aGVHD的作用。

主要发现

  • 第三方ILC2细胞增强allo-HSCT受者生存,治疗需至少4次每周输注。
  • ILC2细胞不能同时表达IL-13和双调蛋白时功能完全丧失。
  • IL-13活性更依赖宿主而非供者骨髓细胞IL-13R表达。

关键数值与推荐

  • 类固醇难治性aGVHD患者诊断后1年生存率<15%。
  • ILC2治疗需至少4次每周输注。

临床怎么用

  • 第三方ILC2细胞有望作为「现货型」试剂用于aGVHD的预防和治疗。

局限性

  • 研究为临床前实验,尚未在患者中验证第三方ILC2的安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD), mediated by the recognition of host major histocompatibility complex/peptide polymorphisms by donor T cells, remains a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). aGVHD most commonly involves the gastrointestinal tract, liver, and skin; symptomatic aGVHD is treated with corticosteroids. Steroid-nonresponsive aGVHD is a significant problem for patients undergoing allo-HSCT, with <15% of these patients alive 1 year after diagnosis. Previously, we found that the infusion of donor innate lymphoid type 2 (ILC2) cells could prevent and treat aGVHD of the lower gastrointestinal tract with no effect on the graft-versus-leukemia response. This approach for clinical translation is cumbersome, as it would require the generation of donor-derived ILC2 cells for each recipient. Thus, the ability to use third-party ILC2 cells would provide an "off-the-shelf" reagent that could be used to treat and/or prevent aGVHD. Here, we show that third-party ILC2 cells enhance the survival of allo-HSCT recipients. Treatment required at least 4 weekly infusions of ILC2 cells. Mechanistically, we show that ILC2 cell function was completely lost if the cells could not express both interleukin-13 (IL-13) and amphiregulin. Finally, we show that the activity of IL-13 has a greater dependence on the expression of the IL-13R on host rather than donor bone marrow cells. The ability to generate third-party ILC2 cells offers a new avenue for the prevention of aGVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bruce DW, Kolupaev O, Laurie SJ, et al. Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD. Blood Adv. 2021. PMID: 34619767. doi:10.1182/bloodadvances.2020001514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。